CK0403, a 9‑aminoacridine, is a potent anti‑cancer agent in human breast cancer cells

Sun,Yuan‑Wan; Chen,Kuen‑Yuan; Kwon,Chul‑Hoon; Chen,Kun‑Ming

doi:10.3892/mmr.2015.4604

CK0403, a 9‑aminoacridine, is a potent anti‑cancer agent in human breast cancer cells

Authors:
- Yuan‑Wan Sun
- Kuen‑Yuan Chen
- Chul‑Hoon Kwon
- Kun‑Ming Chen
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, College of Medicine, Pennsylvania State University, Hershey, PA 17033, USA, Department of Surgery, National Taiwan University Hospital, Taipei 8862, Taiwan, R.O.C., Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, New York, NY 11439, USA
Published online on: November 23, 2015 https://doi.org/10.3892/mmr.2015.4604
Pages: 933-938

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

3‑({4‑[4‑(Acridin‑9‑ylamino)phenylthio]phenyl}(3‑hydroxypropyl)amino)propan‑1‑ol (CK0403) is a sulfur‑containing 9‑anilinoacridine analogue of amsacrine and was found to be more potent than its analogue 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2‑hydroxyethyl)amino)ethan‑1‑ol (CK0402) and amsacrine in the inhibition of the topoisomerase II‑catalyzed decatenation reaction. A previous study by our group reported that CK0402 was effective against numerous breast cancer cell lines, and the combination of CK0402 with herceptin enhanced its activity in HER2(+) SKBR‑3 cells. In order to identify novel chemotherapeutic agents with enhanced potency, the present study explored the potential of CK0403 in the treatment of breast cancer. First, the growth inhibitory activity of CK0403 in the breast cancer cell lines MCF‑7, MDA‑MB‑231, BT474 and SKBR‑3, as well as in the non‑cancerous MCF‑10A cell line, was examined using a sulforhodamine B assay. The results showed that CK0403 exerted more potent growth inhibitory activity than CK0402 in all of the breast cancer cell lines except MCF‑7. SKBR‑3 and MDA‑MB‑231 were the most sensitive cell lines tested, and the combination of CK0403 with herceptin in HER2(+) SKBR‑3 cells enhanced the growth inhibitory activity of CK0403. Analysis of cell cycle alterations induced by CK0403 in SKBR‑3 cells revealed that, similarly to CK0402, CK0403 induced G2/M‑phase arrest with a decreased S- and G0/G1-phase ratio. In addition, it was shown that CK0403 induced apoptosis more effectively than CK0402 in SKBR‑3 cells. Further analysis of autophagy protein 5 (Atg5) indicated that CK0403 induced more cleaved Atg5 than CK0402 and other chemotherapeutic agents tested. Of note, although still relatively potent, CK0403 exhibited reduced growth inhibitory activity under hypoxic conditions, which can induce autophagy. Collectively, the present results supported that CK0403 is highly potent and more effective than CK0402 against estrogen receptor-negative and HER2‑overexpressing breast cancer cell lines, suggesting its future application for chemotherapy in breast cancer.

View Figures

View References

1	Cancer Facts & Figures 2014. American Cancer Society; Atlanta: 2014
2	Gianni L and Valagussa P: Anthracyclines and early breast cancer: The end of an era? J Clin Oncol. 27:1155–1157. 2009. View Article : Google Scholar : PubMed/NCBI
3	O'Shaughnessy J: Liposomal anthracyclines for breast cancer: Overview. Oncologist. 8(Suppl 2): S1–S2. 2003. View Article : Google Scholar
4	Qian BJ, Yan F, Li N, Liu QL, Lin YH, Liu CM, Luo YP, Guo F and Li HZ: MTDH/AEG-1-based DNA vaccine suppresses lung metastasis and enhances chemosensitivity to doxorubicin in breast cancer. Cancer. Immunol Immunother. 60:883–893. 2011. View Article : Google Scholar
5	Weiss RB: The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol. 19:670–686. 1992.PubMed/NCBI
6	Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA and Oliveira PJ: Doxorubicin-induced cardiotoxicity: From bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 34:106–135. 2014. View Article : Google Scholar
7	Ng R, Better N and Green MD: Anticancer agents and cardiotoxicity. Semin Oncol. 33:2–14. 2006. View Article : Google Scholar : PubMed/NCBI
8	Denny WA: DNA-intercalating ligands as anti-cancer drugs: Prospects for future design. Anticancer Drug Des. 4:241–263. 1989.PubMed/NCBI
9	Minotti G, Menna P, Salvatorelli E, Cairo G and Gianni L: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
10	Baguley BC, Holdaway KM and Fray LM: Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance. J Natl Cancer Inst. 82:398–402. 1990. View Article : Google Scholar : PubMed/NCBI
11	Denny WA: Acridine derivatives as chemotherapeutic agents. Curr Med Chem. 9:1655–1665. 2002. View Article : Google Scholar : PubMed/NCBI
12	Nelson EM, Tewey KM and Liu LF: Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA. 81:1361–1365. 1984. View Article : Google Scholar
13	Chen KM, Sun YW, Tang YW, Sun ZY and Kwon CH: Synthesis and antitumor activity of sulfur-containing 9-anilinoacridines. Mol Pharm. 2:118–128. 2005. View Article : Google Scholar : PubMed/NCBI
14	Park SK, Kang H and Kwon CH: Caspase-dependent cell death mediates potent cytotoxicity of sulfide derivatives of 9-anilino-acridine. Anticancer Drugs. 19:381–389. 2008. View Article : Google Scholar : PubMed/NCBI
15	Sun YW, Niu TK, Yang JM, Kwon CH, Chen KY and Chen KM: Potentiation of growth inhibition activity of 2-({4-[4-(acridin-9-ylamino)phenylthio]phenyl}(2-hydroxyethyl) amino) ethan-1-ol (CK0402) by Herceptin in SKBR-3 human breast cancer cells. Exp Ther Med. 1:513–518. 2010.PubMed/NCBI
16	Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, Brunner T and Simon HU: Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol. 8:1124–1132. 2006. View Article : Google Scholar : PubMed/NCBI
17	Baguley BC, Denny WA, Atwell GJ, Finlay GJ, Rewcastle GW, Twigden SJ and Wilson WR: Synthesis, antitumor activity and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide. Cancer Res. 44:3245–3251. 1984.PubMed/NCBI
18	Fyfe D, Price C, Langley RE, Pagonis C, Houghton J, Osborne L, Woll PJ, Gardner C, Baguley BC and Carmichael J: Cancer Research Campaing Phase I/II Trials Committee: A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule. Cancer Chemother Pharmacol. 47:333–337. 2001. View Article : Google Scholar : PubMed/NCBI
19	Bacherikov VA, Chou TC, Dong HJ, Zhang X, Chen CH, Lin YW, Tsai TJ, Lee RZ, Liu LF and Su TL: Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: Synthesis and biological activity. Bioorg Med Chem. 13:3993–4006. 2005. View Article : Google Scholar : PubMed/NCBI
20	Kapuriya N, Kapuriya K, Zhang X, Chou TC, Kakadiya R, Wu YT, Tsai TH, Chen YT, Lee TC, Shah A, et al: Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage. Bioorg Med Chem. 16:5413–5423. 2008. View Article : Google Scholar : PubMed/NCBI
21	Su TL, Lin YW, Chou TC, Zhang X, Bacherikov VA, Chen CH, Liu LF and Tsai TJ: Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: Synthesis and biological activity. J Med Chem. 49:3710–3718. 2006. View Article : Google Scholar : PubMed/NCBI
22	Chun YS, Adusumilli PS and Fong Y: Employing tumor hypoxia for oncolytic therapy in breast cancer. J Mammary Gland Biol Neoplasia. 10:311–318. 2005. View Article : Google Scholar
23	Adamski JK, Estlin EJ and Makin GW: The cellular adaptations to hypoxia as novel therapeutic targets in childhood cancer. Cancer Treat Rev. 34:231–246. 2008. View Article : Google Scholar : PubMed/NCBI
24	Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, et al: Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. Cell Death Dis. 4:e8382013. View Article : Google Scholar : PubMed/NCBI
25	Tamura N, Hirano K, Kishino K, Hashimoto K, Amano O, Shimada J and Sakagami H: Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines. Anticancer Res. 32:4823–4832. 2012.PubMed/NCBI
26	Rubinstein AD and Kimchi A: Life in the balance-a mechanistic view of the crosstalk between autophagy and apoptosis. J Cell Sci. 125:5259–5268. 2012. View Article : Google Scholar